Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 8/20 | 0.51 |
| ▸ | CTSK | P43235 | 7/20 | 0.51 |
| ▸ | CTSB | P07858 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800465 | 0.87 | CTSS (0.58) | BCL2PTPN1CTSSCTSKCTSB | |
| SCHEMBL6800473 | 0.87 | CTSS (0.58) | BCL2PTPN1CTSSCTSKCTSB | |
| SCHEMBL4650210 | 0.85 | GRIA1 (0.52) | CTSSCTSKCTSBCTSL | |
| SCHEMBL13286852 | 0.83 | KLK5 (0.53) | BCL2PTPN1CTSSCTSKCTSB | |
| SCHEMBL13286851 | 0.82 | CTSS (0.49) | BCL2PTPN1CTSSCTSKCTSB | |
| SCHEMBL2791359 | 0.82 | ACE (0.53) | BCL2PTPN1CTSSCTSKCTSB | |
| SCHEMBL2791356 | 0.82 | ACE (0.53) | BCL2PTPN1CTSSCTSKCTSB | |
| SCHEMBL8325214 | 0.82 | ITGA4 (0.51) | BCL2CTSSCTSKCTSBCTSL | |
| SCHEMBL7167610 | 0.82 | ITGA4 (0.51) | BCL2CTSSCTSKCTSBCTSL | |
| SCHEMBL7047054 | 0.81 | ALDH1A1 (0.46) | BCL2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | BCL2 1145/4885PTPN1 5/4885CTSS 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.